1Lancet JE, Gojo I, Gotlib J,et al. Tipifarnib(ZARNESTRA) in previously untreated poor-risk AML and MDS: interim results of a phase 2 trial. Blood, 2003,102:176a.
2Smith DB, Levis M, Beran M, et al. Single-agent CEP701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood, 2004,103:3669-3676.
3Stone RM, Deangelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood, 2005,105:54-60.
4Brown P, Lavis M, Shurtleff S, et al. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood, 2005,105:812-820.
6Bedi A, Barber JP, Bedi GC, et al.BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: amechanism of resistance to multiple anticancer agents. Blood, 1995, 86:1148-1158.
7McGahon A, Bissonnette R, Schmitt M, et al. BCR-ABL maintains resistance of chronicmyelogenous leukemia cells to apoptotic cell death. Blood, 1994,83:1179-1187.
8Qu CK, Yu WM, Azzarelli B, et al. Biased suppression of hematopoiesis and multipledevelopmental defects in chimeric mice containing Shp-2 mutant cells. Mol Cell Biol, 1998,18: 6075-6082.
9Chan RJ, Johnson SA, Li Y, et al. A definitive role of Shp-2 tyrosine phosphatase inmediating embryonic stem cell differentiation and hematopoiesis. Blood, 2003, 102:2074-2080.
10Tauchi T, Feng GS, Shen R, et al. SH2-containing phosphotyrosine phosphatase Syp is atarget of p210bcr-abl tyrosine kinase. J Biol Chem, 1994, 269: 15381-15387.
